Endeavor

New Oral Drug Shows Promise for Patients with HER2-Mutated Lung Cancer

Beamion LUNG-1 trial results highlight zongertinib’s strong tumor control and durable responses

Can Immunotherapy Spare Certain Patients From Surgery?

Dostarlimab offers organ preservation and better quality of life for patients with mismatch repair-deficient tumors

New Immunotherapy Strategy Improves Outcomes in Patients with Advanced Head and Neck Cancer

Patients treated with pembrolizumab were at least 27% less likely to experience cancer recurrence or death

New AI Tool Offers Hope for Early Detection of Cancer Cachexia

The Moffitt model combines imaging and clinical data to improve diagnosis and treatment

Experimental Drug Shows Promise for Patients With Rare Lung Cancer Mutation

New drug targets active form of KRAS, offering hope for lung cancer patients

Moffitt Study Uncovers a Way To Boost Treatment for Aggressive Melanoma

Combination treatment triggers immune response and limits tumor growth

Study Looks To Improve Colorectal Cancer Outcomes Using Blood Biomarkers

The study focuses on the connection between a patient’s immune system and cancer

New Drug Combination Targets KRAS Mutations in Lung Cancer

Study looks at a new way to fight back when KRAS-targeted drugs stop working

How Do Adaptable Cancer Cells Outsmart Treatment?

Moffitt study explores how cancer cells adapt to survive therapy and how stopping that adaptability could lead to better outcomes